$GH Research (GHRS.US)$
Can GH Research's Depression Drug Change Treatment Paradigms? Phase 2b Shows Striking 57.5% Remission Rate

$GH Research (GHRS.US)$ out from slow sideways mover , 3 wins out of 3 today done dor day… expect 1 loss $Dogwood Therapeutics (DWTX.US)$  everything win in recent practice sessions

making big big money here
$HCW Biologics (HCWB.US)$

$GH Research (GHRS.US)$
lost one

wohooo! try here$GH Research (GHRS.US)$
wohooo! try here
$GH Research (GHRS.US)$

wohooo! try here$GH Research (GHRS.US)$
wohooo! try here
$GH Research (GHRS.US)$

wohooo! try here$GH Research (GHRS.US)$
wohooo! try here
$GH Research (GHRS.US)$

$GH Research (GHRS.US)$ GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click here.
The trial recruited 81 patient...